All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

dexamethasone phosphate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	3920	2392-39-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dexamethasone phosphate dexamethasone sodium phosphate decadron dexamethasone phosphoric acid	An anti-inflammatory 9-fluoro-glucocorticoid Molecular weight: 472.45 Formula: C22H30FO8P CLOGP: 0.32 LIPINSKI: 0 HAC: 8 HDO: 4 TPSA: 141.36 ALOGS: -2.21 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Sept. 2, 1959	FDA	MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neutrophil count decreased	212.59	15.37	130	11309	49692	56230936
Febrile neutropenia	181.80	15.37	159	11280	105386	56175242
Platelet count decreased	119.98	15.37	127	11312	106256	56174372
Bone marrow failure	103.45	15.37	67	11372	28219	56252409
Interstitial lung disease	94.16	15.37	84	11355	56979	56223649
Hepatic function abnormal	80.19	15.37	62	11377	34496	56246132
Myelosuppression	78.08	15.37	47	11392	17408	56263220
White blood cell count decreased	76.27	15.37	110	11329	125880	56154748
Neutropenia	74.58	15.37	123	11316	158044	56122584
Anaphylactic shock	73.41	15.37	49	11390	21691	56258937
Pneumocystis jirovecii pneumonia	56.92	15.37	37	11402	15664	56264964
Rheumatoid arthritis	56.60	15.37	6	11433	382598	55898030
Pyrexia	55.72	15.37	199	11240	418574	55862054
Anaemia	53.97	15.37	147	11292	267364	56013264
Colony stimulating factor therapy	49.72	15.37	12	11427	335	56280293
Acute lymphocytic leukaemia recurrent	48.22	15.37	18	11421	2279	56278349
Aortitis	45.11	15.37	14	11425	1012	56279616
Joint swelling	44.26	15.37	4	11435	289796	55990832
Thrombocytopenia	42.79	15.37	89	11350	136135	56144493
Neuropathy peripheral	40.56	15.37	74	11365	102819	56177809
Decreased appetite	38.83	15.37	115	11324	219116	56061512
Radiation necrosis	38.49	15.37	10	11429	379	56280249
Drug ineffective	35.30	15.37	85	11354	918904	55361724
Enterocolitis	34.03	15.37	20	11419	7084	56273544
Allergy test positive	33.23	15.37	9	11430	401	56280227
Central nervous system infection	32.22	15.37	10	11429	723	56279905
Tumour lysis syndrome	32.02	15.37	20	11419	7903	56272725
Left ventricular dilatation	31.81	15.37	9	11430	472	56280156
Peripheral swelling	31.50	15.37	5	11434	234721	56045907
Disseminated intravascular coagulation	30.80	15.37	27	11412	17858	56262770
Erythema	30.68	15.37	85	11354	155854	56124774
Neoplasm progression	30.43	15.37	35	11404	31981	56248647
Eastern Cooperative Oncology Group performance status worsened	30.28	15.37	10	11429	883	56279745
Arthropathy	29.94	15.37	3	11436	200272	56080356
Brain abscess	29.34	15.37	12	11427	1937	56278691
Drug intolerance	28.81	15.37	9	11430	264809	56015819
Disease progression	28.76	15.37	65	11374	105108	56175520
Product dose omission issue	28.30	15.37	4	11435	204749	56075879
Anorectal disorder	28.23	15.37	11	11428	1564	56279064
Alanine aminotransferase increased	28.00	15.37	60	11379	93602	56187026
Procedural vomiting	27.41	15.37	8	11431	469	56280159
Constipation	26.76	15.37	96	11343	201847	56078781
Neoplasm recurrence	26.63	15.37	12	11427	2452	56278176
Hydrocephalus	26.44	15.37	15	11424	4974	56275654
Small intestinal perforation	26.38	15.37	10	11429	1321	56279307
Cytokine release syndrome	26.28	15.37	20	11419	10855	56269773
Systemic lupus erythematosus	26.14	15.37	3	11436	180075	56100553
Liver disorder	25.72	15.37	38	11401	44332	56236296
Neurotoxicity	25.52	15.37	23	11416	15772	56264856
Sinusitis	24.79	15.37	5	11434	197576	56083052
Gastrointestinal perforation	23.64	15.37	12	11427	3187	56277441
Arteriovenous malformation	22.94	15.37	9	11430	1303	56279325
Chemotherapy	21.92	15.37	9	11430	1466	56279162
Abdominal discomfort	21.57	15.37	15	11424	277259	56003369
Posterior reversible encephalopathy syndrome	21.48	15.37	21	11418	15939	56264689
Arteritis	21.45	15.37	7	11432	595	56280033
Osteonecrosis of jaw	21.43	15.37	30	11409	33328	56247300
Multiple organ dysfunction syndrome	20.83	15.37	38	11401	52732	56227896
Malignant neoplasm progression	20.69	15.37	46	11393	73541	56207087
Klebsiella infection	20.38	15.37	15	11424	7741	56272887
Large intestine perforation	20.22	15.37	15	11424	7836	56272792
Pancytopenia	20.11	15.37	51	11388	88664	56191964
Ileus	20.07	15.37	19	11420	13863	56266765
Stomatitis	20.05	15.37	62	11377	120748	56159880
Respiratory failure	19.86	15.37	53	11386	95009	56185619
Procedural nausea	19.84	15.37	7	11432	755	56279873
Nasal dryness	18.98	15.37	11	11428	3795	56276833
Blood phosphorus decreased	18.48	15.37	11	11428	3986	56276642
Hypokalaemia	18.08	15.37	51	11388	94386	56186242
Blood potassium abnormal	17.93	15.37	9	11430	2336	56278292
Dermatitis acneiform	17.64	15.37	11	11428	4333	56276295
Performance status decreased	17.63	15.37	10	11429	3313	56277315
Drug hypersensitivity	17.58	15.37	18	11421	275187	56005441
Nausea	17.51	15.37	234	11205	763944	55516684
Cytopenia	17.35	15.37	15	11424	9740	56270888
Sepsis	17.26	15.37	65	11374	139775	56140853
Myelopathy	16.89	15.37	9	11430	2639	56277989
Wound	16.42	15.37	4	11435	138800	56141828
Aspartate aminotransferase increased	16.20	15.37	45	11394	82557	56198071
Seizure	16.14	15.37	59	11380	125060	56155568
Weight increased	15.87	15.37	14	11425	229689	56050939
Cerebral infarction	15.60	15.37	21	11418	22484	56258144
Condition aggravated	15.57	15.37	29	11410	344869	55935759
Vomiting	15.56	15.37	162	11277	498066	55782562

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Choroiditis	189.76	16.82	50	11650	1082	31684562
Endophthalmitis	177.47	16.82	62	11638	3554	31682090
Neutrophil count decreased	167.72	16.82	138	11562	46256	31639388
Intraocular pressure increased	145.31	16.82	59	11641	5128	31680516
Platelet count decreased	134.96	16.82	184	11516	110251	31575393
Febrile neutropenia	128.20	16.82	189	11511	121660	31563984
White blood cell count decreased	111.83	16.82	149	11551	87249	31598395
Interstitial lung disease	111.55	16.82	125	11575	61278	31624366
Uveitis	111.15	16.82	53	11647	6763	31678881
Eye pain	102.13	16.82	61	11639	12243	31673401
Visual acuity reduced	82.71	16.82	58	11642	15285	31670359
Decreased appetite	65.52	16.82	162	11538	153055	31532589
Disseminated intravascular coagulation	61.67	16.82	55	11645	20482	31665162
Large intestine perforation	53.53	16.82	34	11666	7602	31678042
Myelosuppression	48.89	16.82	42	11658	14878	31670766
Pyrexia	48.68	16.82	231	11469	303609	31382035
Neutropenia	48.34	16.82	137	11563	140227	31545417
Tumour lysis syndrome	47.77	16.82	42	11658	15343	31670301
Bone marrow failure	42.41	16.82	52	11648	27956	31657688
Neoplasm progression	37.99	16.82	42	11658	20230	31665414
Hepatic function abnormal	34.91	16.82	58	11642	41164	31644480
Hiccups	34.26	16.82	28	11672	9259	31676385
Strongyloidiasis	33.05	16.82	17	11683	2549	31683095
Stomatitis	32.74	16.82	55	11645	39383	31646261
Drug interaction	28.83	16.82	21	11679	208522	31477122
Hypoalbuminaemia	28.18	16.82	27	11673	11001	31674643
Anaemia	26.88	16.82	152	11548	213370	31472274
Gastrointestinal perforation	25.02	16.82	16	11684	3616	31682028
Capillary nail refill test abnormal	24.40	16.82	5	11695	33	31685611
Anaphylactic shock	24.27	16.82	28	11672	14117	31671527
Paronychia	24.24	16.82	15	11685	3203	31682441
Malignant neoplasm progression	23.23	16.82	73	11627	78925	31606719
Disease progression	22.51	16.82	79	11621	90385	31595259
Drug abuse	22.29	16.82	3	11697	87755	31597889
JC virus infection	22.24	16.82	12	11688	1982	31683662
Off label use	22.14	16.82	210	11490	347064	31338580
Toxicity to various agents	21.72	16.82	21	11679	181466	31504178
Tumour necrosis	21.72	16.82	10	11690	1177	31684467
Septic shock	21.19	16.82	63	11637	66095	31619549
Eye complication associated with device	20.72	16.82	3	11697	0	31685644
Fall	20.61	16.82	23	11677	186066	31499578
Dermatitis acneiform	20.46	16.82	17	11683	5750	31679894
Hyperglycaemia	20.43	16.82	43	11657	36433	31649211
Lymphocyte count decreased	20.14	16.82	31	11669	20618	31665026
Product dose omission issue	20.00	16.82	7	11693	105579	31580065
Periodontitis	19.98	16.82	11	11689	1891	31683753
Myocardial infarction	19.09	16.82	9	11691	113445	31572199
PaO2/FiO2 ratio decreased	18.73	16.82	4	11696	33	31685611
Angle closure glaucoma	17.78	16.82	8	11692	893	31684751
Uveitis-glaucoma-hyphaema syndrome	17.77	16.82	3	11697	5	31685639
Blood lactate dehydrogenase increased	17.72	16.82	29	11671	20310	31665334
Immune effector cell-associated neurotoxicity syndrome	17.27	16.82	11	11689	2468	31683176
Pneumocystis jirovecii pneumonia	17.24	16.82	27	11673	18224	31667420

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neutrophil count decreased	326.11	14.75	238	20814	83318	70824074
Febrile neutropenia	291.43	14.75	330	20722	203988	70703404
Platelet count decreased	247.47	14.75	284	20768	177938	70729454
Choroiditis	183.93	14.75	48	21004	1253	70906139
Interstitial lung disease	171.34	14.75	182	20870	104503	70802889
White blood cell count decreased	166.94	14.75	228	20824	169913	70737479
Endophthalmitis	160.98	14.75	63	20989	6192	70901200
Bone marrow failure	135.49	14.75	114	20938	48896	70858496
Intraocular pressure increased	120.79	14.75	57	20995	8844	70898548
Myelosuppression	110.96	14.75	83	20969	30062	70877330
Hepatic function abnormal	109.02	14.75	117	20935	67879	70839513
Neutropenia	96.19	14.75	226	20826	256930	70650462
Pyrexia	95.58	14.75	394	20658	606558	70300834
Decreased appetite	92.15	14.75	247	20805	304533	70602859
Disseminated intravascular coagulation	88.43	14.75	76	20976	33522	70873870
Uveitis	83.29	14.75	53	20999	14792	70892600
Tumour lysis syndrome	79.02	14.75	59	20993	21301	70886091
Anaphylactic shock	78.49	14.75	70	20982	32420	70874972
Large intestine perforation	71.28	14.75	46	21006	13149	70894243
Visual acuity reduced	69.10	14.75	61	20991	27869	70879523
Eye pain	67.94	14.75	66	20986	34036	70873356
Pneumocystis jirovecii pneumonia	63.30	14.75	60	20992	30022	70877370
Anaemia	62.59	14.75	261	20791	403162	70504230
Rheumatoid arthritis	62.15	14.75	7	21045	291798	70615594
Neoplasm progression	59.10	14.75	70	20982	45158	70862234
Colony stimulating factor therapy	53.00	14.75	15	21037	534	70906858
Joint swelling	51.65	14.75	7	21045	253204	70654188
Malignant neoplasm progression	50.98	14.75	112	20940	121627	70785765
Neuropathy peripheral	48.95	14.75	113	20939	126783	70780609
Thrombocytopenia	46.24	14.75	166	20886	238944	70668448
Strongyloidiasis	44.92	14.75	22	21030	3701	70903691
Acute lymphocytic leukaemia recurrent	44.73	14.75	24	21028	4880	70902512
Peripheral swelling	42.81	14.75	9	21043	236554	70670838
Aortitis	42.71	14.75	16	21036	1395	70905997
Drug intolerance	42.07	14.75	8	21044	225679	70681713
Gastrointestinal perforation	41.43	14.75	24	21028	5657	70901735
Stomatitis	39.58	14.75	105	20947	128406	70778986
Enterocolitis	39.43	14.75	32	21020	13034	70894358
Disease progression	38.51	14.75	118	20934	156554	70750838
Fatigue	38.13	14.75	122	20930	824197	70083195
Toxicity to various agents	37.42	14.75	35	21017	382137	70525255
Septic shock	36.90	14.75	94	20958	112164	70795228
Hypoalbuminaemia	36.20	14.75	36	21016	19086	70888306
Product dose omission issue	35.97	14.75	10	21042	217458	70689934
Hiccups	35.71	14.75	26	21026	9026	70898366
Fall	34.49	14.75	49	21003	444047	70463345
Radiation necrosis	34.36	14.75	10	21042	394	70906998
Allergy test positive	33.38	14.75	10	21042	436	70906956
Overdose	31.66	14.75	6	21046	169739	70737653
Alanine aminotransferase increased	31.61	14.75	106	20946	147374	70760018
Small intestinal perforation	31.07	14.75	16	21036	2993	70904399
Drug abuse	30.18	14.75	4	21048	147252	70760140
Anorectal disorder	30.12	14.75	14	21038	2097	70905295
Erythema	29.98	14.75	128	20924	199435	70707957
Hyperglycaemia	29.93	14.75	62	20990	64610	70842782
Cytokine release syndrome	29.78	14.75	38	21014	26429	70880963
Paronychia	29.47	14.75	21	21031	7053	70900339
Dermatitis acneiform	29.32	14.75	23	21029	8922	70898470
Tumour necrosis	29.26	14.75	13	21039	1754	70905638
Posterior reversible encephalopathy syndrome	28.99	14.75	36	21016	24366	70883026
Liver disorder	28.47	14.75	59	20993	61509	70845883
Periodontitis	28.20	14.75	17	21035	4311	70903081
Arthralgia	27.26	14.75	69	20983	503321	70404071
Hydrocephalus	26.96	14.75	21	21031	8064	70899328
Central nervous system infection	26.73	14.75	11	21041	1230	70906162
Constipation	26.45	14.75	146	20906	252292	70655100
Blood pressure decreased	25.40	14.75	72	20980	91443	70815949
Klebsiella infection	25.39	14.75	26	21026	14266	70893126
Hypokalaemia	25.25	14.75	91	20961	131097	70776295
Therapeutic product effect decreased	24.74	14.75	6	21046	143012	70764380
Myocardial infarction	24.70	14.75	10	21042	171635	70735757
Sepsis	24.66	14.75	140	20912	244405	70662987
Confusional state	24.50	14.75	29	21023	284369	70623023
Cerebral infarction	24.49	14.75	45	21007	42964	70864428
Aspartate aminotransferase increased	24.37	14.75	88	20964	126890	70780502
Abdominal discomfort	24.30	14.75	17	21035	214641	70692751
Peritonitis	23.99	14.75	34	21018	26125	70881267
Capillary nail refill test abnormal	23.92	14.75	5	21047	47	70907345
Pain	23.79	14.75	101	20951	628715	70278677
Neurotoxicity	23.37	14.75	36	21016	29790	70877602
Blood lactate dehydrogenase increased	22.90	14.75	39	21013	35088	70872304
Sinusitis	22.55	14.75	11	21041	169184	70738208
Brain abscess	22.42	14.75	15	21037	4551	70902841
Musculoskeletal stiffness	22.28	14.75	8	21044	147752	70759640
Neoplasm recurrence	21.93	14.75	14	21038	3927	70903465
Gait disturbance	21.84	14.75	14	21038	185092	70722300
Left ventricular dilatation	21.77	14.75	9	21043	1019	70906373
Drug hypersensitivity	21.31	14.75	28	21024	262431	70644961
Cytopenia	21.29	14.75	26	21026	17297	70890095
Osteonecrosis of jaw	20.99	14.75	41	21011	40961	70866431
Eastern Cooperative Oncology Group performance status worsened	20.90	14.75	10	21042	1598	70905794
Chemotherapy	20.86	14.75	10	21042	1606	70905786
Drug interaction	20.85	14.75	52	21000	381389	70526003
Weight increased	20.56	14.75	25	21027	242306	70665086
Systemic lupus erythematosus	20.33	14.75	3	21049	101899	70805493
Pulmonary artery thrombosis	19.98	14.75	9	21043	1254	70906138
PaO2/FiO2 ratio decreased	19.94	14.75	4	21048	30	70907362
Psoriasis	19.40	14.75	3	21049	98430	70808962
Immune effector cell-associated neurotoxicity syndrome	19.37	14.75	13	21039	3965	70903427
Aspergillus infection	19.08	14.75	25	21027	17843	70889549
Multiple organ dysfunction syndrome	18.98	14.75	73	20979	108442	70798950
Myelopathy	18.59	14.75	13	21039	4238	70903154
Macular oedema	18.51	14.75	14	21038	5148	70902244
Pain in extremity	18.49	14.75	44	21008	328038	70579354
Anterior chamber flare	18.24	14.75	5	21047	158	70907234
Peripheral sensory neuropathy	17.93	14.75	20	21032	12090	70895302
Arteriovenous malformation	17.59	14.75	9	21043	1661	70905731
Child-Pugh-Turcotte score abnormal	17.47	14.75	3	21049	8	70907384
Ileus	17.26	14.75	28	21024	24209	70883183
Bacteraemia	17.11	14.75	31	21021	29278	70878114
Pancytopenia	16.89	14.75	89	20963	151018	70756374
Respiratory failure	16.60	14.75	96	20956	168639	70738753
Swelling	16.47	14.75	19	21033	188520	70718872
Vomiting	16.44	14.75	257	20795	592854	70314538
Arteritis	16.40	14.75	7	21045	858	70906534
Keratolysis exfoliativa acquired	16.35	14.75	3	21049	13	70907379
Cardiac failure congestive	16.31	14.75	10	21042	135447	70771945
Drug ineffective	16.17	14.75	190	20862	939562	69967830
Cytomegalovirus chorioretinitis	16.04	14.75	13	21039	5285	70902107
Chromosomal deletion	15.93	14.75	4	21048	89	70907303
Blood potassium abnormal	15.82	14.75	10	21042	2758	70904634
Pneumonia bacterial	15.81	14.75	22	21030	16619	70890773
Memory impairment	15.80	14.75	4	21048	92637	70814755
Nasopharyngitis	15.79	14.75	26	21026	222180	70685212
Wound	15.48	14.75	5	21047	98727	70808665
Nasal dryness	15.23	14.75	11	21041	3772	70903620
Fibrin degradation products increased	14.94	14.75	5	21047	313	70907079
Headache	14.90	14.75	106	20946	580299	70327093
Pneumonia	14.90	14.75	254	20798	595978	70311414
Eye complication associated with device	14.78	14.75	3	21049	24	70907368

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA MoA	N0000175450	Corticosteroid Hormone Receptor Agonists
FDA EPC	N0000175576	Corticosteroid
MeSH PA	D005938	Glucocorticoids
MeSH PA	D006728	Hormones
CHEBI has role	CHEBI:63562	glucocorticoid receptor agonists
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000932	Antiemetics
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D018931	Antineoplastic Agents, Hormonal
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018373	Peripheral Nervous System Agents
CHEBI has role	CHEBI:35472	anti-inflammatory drugs
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:35705	immunosuppressive agents
CHEBI has role	CHEBI:37962	adrenergic agents
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:78298	environmental contaminants

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Inflammation	Indication
Cattle	Primary bovine ketosis	Indication
Cattle	Inflammation	Indication
Dogs	Inflammation	Indication
Horses	Inflammation	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Dex-A-Vet Injection	Bimeda Animal Health Limited	1
Dex-A-Vet Injection	Bimeda Animal Health Limited	1
Dexamethasone Sodium Phosphate Inj.	Cronus Pharma Specialities India Private Limited	1
Dexium-SP	Bimeda Animal Health Limited	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	1.75	acidic
pKa2	6.8	acidic
pKa3	11.06	acidic
pKa4	13.94	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN	AGONIST	IC50	9.30		CHEMBL	CHEMBL
Mineralocorticoid receptor	Nuclear hormone receptor	P08235	MCR_HUMAN		Ki	9.44		CHEMBL
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN		Ki	5.85		CHEMBL
Progesterone receptor	Nuclear hormone receptor	P06401	PRGR_HUMAN		Ki	6.25		CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		Ki	4.79		CHEMBL
Fatty acid-binding protein, liver	Unclassified		FABPL_RAT		Ki	4.66		CHEMBL
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	5.52		CHEMBL
Glucocorticoid receptor	Transcription factor		GCR_RAT		IC50	7.66		CHEMBL

External reference:

ID	Source
4020650	VUID
N0000148296	NUI
D00975	KEGG_DRUG
312-93-6	SECONDARY_CAS_RN
4017922	VANDF
4017923	VANDF
4020650	VANDF
C0770565	UMLSCUI
CHEBI:4462	CHEBI
CHEBI:41879	CHEBI
DEX	PDB_CHEM_ID
CHEMBL1201302	ChEMBL_ID
CHEMBL2021430	ChEMBL_ID
CHEMBL1200637	ChEMBL_ID
C004180	MESH_SUPPLEMENTAL_RECORD_UI
2BP70L44PR	UNII
9400	PUBCHEM_CID
DB01234	DRUGBANK_ID
227682	RXNORM
3245	MMSL
35380	MMSL
39663	MMSL
4552	MMSL
4554	MMSL
6848	MMSL
776	MMSL
d00206	MMSL
002174	NDDF
002176	NDDF
002177	NDDF
372584003	SNOMEDCT_US
396016009	SNOMEDCT_US
396017000	SNOMEDCT_US
7561000	SNOMEDCT_US
C0011777	UMLSCUI
CHEMBL1530428	ChEMBL_ID
CHEMBL384467	ChEMBL_ID
816	INN_ID
D003907	MESH_DESCRIPTOR_UI
5743	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9841	INJECTION, SOLUTION	4 mg	INTRA-ARTICULAR	ANDA	12 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9841	INJECTION, SOLUTION	4 mg	INTRA-ARTICULAR	ANDA	12 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9842	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	11 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9842	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	11 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9843	INJECTION, SOLUTION	4 mg	INTRAVENOUS	ANDA	9 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9843	INJECTION, SOLUTION	4 mg	INTRAVENOUS	ANDA	9 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0367	INJECTION	10 mg	INTRAMUSCULAR	ANDA	13 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6145	INJECTION	4 mg	INTRA-ARTICULAR	ANDA	13 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6146	INJECTION	4 mg	INTRA-ARTICULAR	ANDA	13 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	11695-1411	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	15 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	16590-068	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	11 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	21695-847	SOLUTION	1 mg	OPHTHALMIC	ANDA	18 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	24208-720	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	16 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	24208-720	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	16 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	42254-088	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	15 sections
Dexamethasone Sodium Phosphate	Human Prescription Drug Label	1	50090-0627	INJECTION, SOLUTION	4 mg	INTRAMUSCULAR	ANDA	12 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1922	INJECTION, SOLUTION	4 mg	INTRA-ARTICULAR	ANDA	13 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2313	INJECTION, SOLUTION	4 mg	INTRA-ARTICULAR	ANDA	13 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2313	INJECTION, SOLUTION	4 mg	INTRA-ARTICULAR	ANDA	13 sections
DEXAMETHASONE SODIUM PHOSPHATE	Human Prescription Drug Label	1	50090-3300	INJECTION, SOLUTION	4 mg	INTRAVENOUS	ANDA	10 sections
DEXAMETHASONE SODIUM PHOSPHATE	Human Prescription Drug Label	1	50090-3300	INJECTION, SOLUTION	4 mg	INTRAVENOUS	ANDA	10 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3541	INJECTION	10 mg	INTRAMUSCULAR	ANDA	12 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3541	INJECTION	10 mg	INTRAMUSCULAR	ANDA	12 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4567	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	9 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1297	INJECTION	4 mg	SOFT TISSUE	ANDA	10 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1343	INJECTION	10 mg	INTRAMUSCULAR	ANDA	10 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1370	INJECTION, SOLUTION	4 mg	INTRAMUSCULAR	ANDA	13 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1391	INJECTION, SOLUTION	10 mg	INTRAMUSCULAR	ANDA	13 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1432	INJECTION, SOLUTION	4 mg	INTRAMUSCULAR	ANDA	10 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1541	INJECTION	100 mg	INTRAMUSCULAR	ANDA	10 sections